血清CYFRA21—1免疫放射分析在非小细胞肺癌诊断中的临床价值

ＣＹＦＲＡ２１－１是细胞角蛋白１９的片段（ＣＫ１９）。免疫放射法（ＩＲＭＡ）测定１３３例肺癌患者血清中ＣＹＦＲＡ２１－１水平，与血清神经元特异性烯醇化酶（ＮＳＥ）作比较，初步观察了５例非小细胞肺癌患者血清ＣＹＦＲＡ２１－１在治疗过程中的动态变化。结果表明肺癌患者血清ＣＹＦＲＡ２１－１水平明显高于肺良性疾患组和正常对照组；在肺癌患者，血清ＣＹＦＲＡ２１－１水平升高主要出现在非小细胞肺癌组，尤其鳞癌组     

血清CYFRA21—1在肿瘤诊断中的临床价值

目的：探讨ＣＹＦＲＡ２１－１在肺癌、喉癌和消化道肿瘤中的诊断价值。方法：应用酶联免疫方法对８２例肺癌、１８例喉癌和７４例消化道肿瘤测试血清ＣＹＦＲＡ２１－１水平。结果：①肺癌ＣＹＦＲＡ２１－１阳性率为７９．３％,特异性为９２．５％,准确率为８３．６％,明显高于其他肿瘤;②肿瘤转移患者血清ＣＹＦＲＡ２１－１水平明显高于未转移患者;③肺癌治疗前后血清ＣＹＦＲＡ２１－１水平有显著差异,治疗后明显下降;④     

CYFRA21—1等肿瘤标记物在肺癌诊断中的应用

ＣＹＦＲＡ２１┐１等肿瘤标记物在肺癌诊断中的应用马兰艾桂萍许佩珉高德芹细胞角质蛋白１９（ＣＹＦＲＡ２１－１）是一种新的肿瘤标志物，在肺癌组织中含量较高，并可溶于血清中，可借助两个单克隆抗体用酶联免疫法测定。我们以ＣＹＦＲＡ２１－１与癌胚抗原（ＣＥＡ）...     

CYFRA21-1在肺癌诊断、疗效监测及预后观察的临床意义

目的：研究ＣＹＦＲＡ２１－１在肺癌诊断、疗效监测和预后观察的临床意义及应用价值。方法：选自本院的３２７例肺癌，２９７例肺部良性疾病的住院和门诊病人应用放射免疫分析法（ＩＲＭＡ）检测了ＣＹＦＲＡ２１１的血清水平。结果：肺癌组水平１６９±８４ｎｇ／ｍｌ，非肿瘤组水平１９±１６ｎｇ／ｍｌ，（Ｐ＜０００１）差异显著。肺癌阳性率６２４％，良性疾病阳性率５％。测定灵敏度为６２４％特异性为９４５％，准确率７７９％。肺癌病人随病期的增加，血清ＣＹＦＲＡ２１１含量也随之上升（Ｐ＜００２）。对８例肺癌手术病人和１０例化疗病人含量变化分析，在手术３周～５周后，血清含量由术前的６４±３１ｎｇ／ｍｌ，降到１８±０６ｎｇ／ｍｌ，１０例化疗病人，其中８例血清含量均有降低，临床证实均有良好的治疗效果，另２例临床证实治疗无效，血清ＣＹＦＲＡ２１１水平相应增高。结论：血清ＣＹＦＲＡ２１－１的水平与肿瘤病人的临床表现有直接的相关性，提示测定肺癌患者血清ＣＹＦＲＡ２１１水平对诊断和预后有重要的临床应用价值     

血清CYFRA21—1,CEA和NSE联合检测对肺癌的诊断价值

血清ＣＹＦＲＡ２１┐１、ＣＥＡ和ＮＳＥ联合检测对肺癌的诊断价值李蓉李睿张哲舫研究已有标记物的有效联合检测，是目前肺癌肿瘤标记物的研究方向之一。为此，我们比较血清中细胞角蛋白１９片段（ＣＹＦＲＡ２１－１）、癌胚抗原（ＣＥＡ）和神经元特异性烯醇化酶（ＮＳ...     

乳腺癌患者血清ＣＹＦＲＡ２１—１检测的临床价值

目的：检测乳腺癌患者血清中ＣＹＦＲＡ２１－１水平，探讨其在乳腺癌的术前诊断和术后随访监测中的应用价值。方法：采用放免法测定３４例乳腺良性疾病患者术前、４７例乳腺癌患者术前和术后４周及５６例乳腺癌术后随访患者的血清ＣＹＦＲＡ２１－１水平，进行对照分析。结果：乳腺良性疾病无１例阳性；乳腺癌术前阳性率仅２１％，但两者血清ＣＹＦＲＡ２１－１水平有明显差异；４７例乳腺癌患者手术前与术后４周血清ＣＹＦＲＡ２１－１水平相比有显著差异：５６例乳腺癌患者术后随访例转移复发者中６例阳性，无转移复发者均阴性。转移复发者血清ＣＹＦＲＡ２１－１水平较无转移复发者明显增高，两者相比差异有极显著性。结论：血清ＣＹＦＲＡ２１－１检测对乳腺癌特异性高，但对乳腺癌术前诊断价值不大，对乳腺癌转移复发的监测有非常重要意义。     

评价酶联免疫检测血清CYFRA21—1对非小细胞肺癌的诊断价值

目的评价检测ＣＹＦＲＡ２１┐１对非小细胞肺癌的诊断价值。方法用ＥＬＩＳＡ法测定７０例肺癌（ＬＣ）其中４７例非小细胞肺癌（ＮＳＣＬＣ），３例小细胞肺癌（ＳＣＬＣ）和２０例未分型肺癌、６４例肺部良性疾病患者及４０例健康人血清ＣＹＦＲＡ２１┐１浓度。试验的诊断性能用相对操作特征（ＲＯＣ）分析法估测之。结果测得全阈诊断准确率（ＯｖｅｒａｌＤｉａｇ┐ｎｏｓｔｉｃＡｃｃｕｒａｃｉｅｓ）ＬＣ为０．７５、ＮＳＣＬＣ为０．７６，ＳＱＣ为０．８３，ＡＤＥ为０．６７和ＳＣＬＣ为０．３８。在相应于特异性为０．９５的界定值３．４７μｇ／Ｌ处，各型的灵敏度分别为ＳＱＣ０．６２，ＬＣ０．５３，ＮＳＣＬＣ０．５１，ＡＤＥ０．４８和ＳＣＬＣ０．００。结论结果显示ＣＹＦＲＡ２１┐１是ＮＳＣＬＣ较灵敏和特异的一个标志物。未观察到ＴＮＭ各期间该标志物的平均水平有明显的差异；然而异常升高水平的患者的比例随病期的进展而显著增加，提示一系列检测ＣＹＦＲＡ２１┐１水平可能有助于监查ＮＳＣＬＣ患者的疗效。     

CYFRA21—1,CEA联合测定对癌性胸水的诊断价值

检测１１８例胸水ＣＹＦＲＡ２１－１和ＣＥＡ浓度以及ＡＤＡ活性。其中癌性不６７例，结核性胸水４０例，其它良性渗漏液１１例。ＣＹＦＲＡ２１－１对癌胸水的敏感度为６２．６％，特异度为９０．２％，ＣＥＡ的敏感度为５５．２％，特异度为１００％。联合测定ＣＹＦＲＡ２１－１和ＣＥＡ对癌性胸水的敏感度可提高到８５．１％，其临床应用值值得重视。     

胸水肿瘤标志物测定的临床诊断价值

［目的］观察胸水中肿瘤标志物测定值对临床诊断的价值。［方法］分别测定４６例胸腔积液患者的血清与胸水肿瘤标志物（ＣＥＡ、ＮＳＥ、 ＣＡ２４２、 ＣＹＦＲＡ２１－１）含量,其中癌性积液２８例,良性积液１８例。［结果］发现胸水中肿瘤标志物含量明显高于血清水平;ＣＥＡ、ＮＥＳ、ＣＡ２４２三者联合应用在胸水中敏感性高达９２．８％,特异性９６．２％,而血清中相应为７５．１％,８７．５％;ＣＹＦＲＡ２１－１在良性组中虽阳性率较高,但数值明显低于癌性积液组（Ｐ＜０．０１）。［结论］测定胸水肿瘤标志物对恶性积液的诊断具有临床应用价值。     

CYFRA21－1检测对肺癌的诊断价值

ＣＹＦＲＡ２１－１检测对肺癌的诊断价值曾亮，乔玉磊，仇德惠，顾伟光，陈可靖上海医科大学中山医院胸外科，上海医科大学中山医院核医学科（上海２０００３２）ＣＹＦＲＡ２１－１是细胞角蛋白的一种亚单位片段，又称细胞角蛋白１９，为一种酸性细胞蛋白，分子量４０Ｋ...     

Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer

Purpose

This study investigated the preoperative serum levels of CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer.

Subjects

This study evaluated 341 patients who had undergone a complete resection for stage I NSCLC between 2002 and 2008.

Results

The patients included 193 males and 148 females. The mean age of the patients was 69.2 years (range: 19–88). The histological types included 264 adenocarcinomas, 56 squamous cell carcinomas, 11 large cell carcinomas, and 10 other types of carcinoma. A pneumonectomy was performed in 2 patients, a bilobectomy in 7, a lobectomy in 255, a segmentectomy in 46, and partial resection of the lung in 31 patients. The positive rates for CYFRA 21-1 in the adenocarcinoma and squamous cell carcinoma patients were 33.3% and 76.8%, respectively. The positive rates for CEA in adenocarcinoma and squamous cell carcinoma patients were 23.8% and 26.8%, respectively. The 5-year survival rate after surgery in the normal CYFRA 21-1 group and the high CYFRA 21-1 groups were 92.8% and 75.4%, respectively, in the patients with stage I NSCLC. There was a significant difference between the 2 groups (p < 0.0001). The 5-year survival rate according to the serum level of CEA in the patients with stage I NSCLC were 88.3% for the normal group and 76.3% for the high group. In a multivariate analysis using the variables found to be significant prognostic factors in univariate analysis, a high CYFRA 21-1 level was found to be a significant independent prognostic factor (95% confidence interval 1.213–5.442, p = 0.014).

Conclusion

A high preoperative CYFRA 21-1 level was a significant independent prognostic factor in patients with stage I NSCLC. The patients with a high CYFRA 21-1 level should carefully followed-up to rule out occult metastasis. Further clinical studies will be necessary to evaluate the efficacy of adjuvant therapy for the patients selected according to this criterion.     

Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival

Prognostic implication of serum cytokeratin 19 fragments (CYFRA 21-1) was explored in 60 advanced NSCLC patients, whereas in 45 patients assessable for serological response a >or=35% CYFRA 21-1 decline after two chemotherapy cycles was strongly associated with non-progression (NP), defined as a sum of objective response (OR)+stable disease (P<0.0001) and survival (P=0.0002). Association of OR with survival was not significant. In multivariate survival analysis, >or=35% marker decline and radiological NP status were found as major determinants of prolonged survival with RR: 0.37 (P=0.01) and 0.63 (P=0.01), respectively. In advanced NSCLC patients, NP reflects therapeutic efficacy better than traditional OR. CYFRA 21-1 >or=35% decline seems to be a reliable surrogate marker of treatment efficacy in terms of survival.     

Preoperative CYFRA 21-1 level as a prognostic indicator in resected primary squamous cell lung cancer.

The CYFRA 21-1 assay is a test that has been developed recently for detection of a cytokeratin 19 fragment in serum. A diagnostic role for CYFRA 21-1 has already been proposed. The question of whether this marker is prognostically significant is important in clarifying the role of CYFRA 21-1 in clinical practice. The aim of this study was to evaluate the prognostic significance of elevated preoperative CYFRA 21-1 levels in patients with resected primary squamous-cell lung cancer (SqCC). Serum levels of CYFRA 21-1 were measured using an immunoradiometric assay (CIS bio) in 91 patients with operable SqCC. Survival and disease-free survival curves related to initial levels of this marker were estimated using the Kaplan-Meier method. In the univariate analysis the log-rank test and the log-rank test for trend were used. In the multivariate analysis the stratified log-rank test and the proportional hazard model were used. Elevated preoperative CYFRA 21-1 levels were identified in 55% of patients with SqCC. The number of patients with elevated levels of this marker increased with TNM stage (P = 0.0001). In univariate analysis elevated levels of CYFRA 21-1 were significantly associated with poor overall survival (P < 0.00005) and with disease-free survival (P < 0.00005). In multivariate analysis elevated levels of this marker were also found to be associated with poor overall and disease-free survival (P = 0.01 and P = 0.003 respectively). In conclusion, CYFRA 21-1 may be an independent prognostic parameter of survival and tumour relapse in SqCC and may be useful in identifying resected SqCC patients at high risk of treatment failure.     

肺癌患者血清细胞角蛋白19片段与病理类型及吸烟的相关性分析

目的:探讨肺癌患者血清肿瘤标记物细胞角蛋白19片段(CYFRA21-1)与肿瘤病理类型和吸烟的相关性和对肺癌的诊断价值。方法:应用化学发光技术测定经病理确诊的187例肺癌患者、33例肺良性疾病和健康对照的CYFRA21-1水平。应用SPSS18统计软件包分析病理类型、吸烟和CYFRA21-1间的关系。结果:187例肺癌患者血清中CYFRA21-1水平明显高于非良性病和健康对照组,肺良性病与健康对照组比无显著差别;187例患者吸烟者123例(65.7%),不吸烟者64例(34.2%)。在肺鳞癌、肺腺癌及小细胞肺癌中,吸烟者分别为72.9%、52.3%和73.0%,各组间行卡方分析χ2=8.03 P=0.018;血清CYFRA21-1在鳞癌、腺癌和小细胞肺癌的水平分别为13.96±22.84、7.12±12.22、3.66±4.66,各组间有显著差别(F=5.58,P=0.004);阳性率分别为58.8%、38.5%和32.4%,χ2=9.82,P=0.007,但腺癌与小细胞癌比无显著差别。cfyra211阳性率在非吸烟组、轻、中、重度吸烟组分别为39.1%、61.5%、52.2%和43.0%,四组间阳性率有显著差别,以非吸烟组为最低,重度吸烟组次之(χ2=9.542 P=0.023)。结论:cfyra211在肺鳞癌、腺癌和小细胞癌中肺鳞癌的水平和阳性率最高;肺鳞癌和小细胞癌吸烟者占大多数,cfyra211水平与吸烟无明显的相关性,但对肺鳞癌的诊断有一定的价值。     

Cyfra21-1对进展期非小细胞肺癌一线化疗疗效的早期预测作用

Objective: In an era of ever evolving, promising new therapies for advanced non small cell lung cancer (NSCLC), early predictors of response to therapy, are needed. We evaluated early variations in CYFRA 21-1 serum levels of patients with advanced NSCLC receiving first line chemotherapy and correlated the results with objective tumor response. Methods: 29 consecutive, previously untreated, patients of advanced non small cell lung cancer, with measurable disease on CT scan were evaluated. All patients were treated with conventional systemic chemotherapy, although the choice of chemotherapy was left to the discretion of the treating physicians. Serum samples were obtained immediately before the start of 1st and 2nd cycles of chemotherapy. CYFRA 21-1 was measured with an electrochemiluminescense immunoassay on an automatic analyzer (Elecsys 2000; Roche Diagnostics). Response was evaluated using Response evaluation criteria in solid tumors (RECIST) criteria. Results: 10 patients had partial response, 9 patients had stable disease and 9 had progressive disease. None of the patients had complete response. 21/29 (72%) patients had an elevated baseline value of CYFRA 21-1. 62% pa- tients (18/29) had a decrease in CYFRA 21-1 after 1 cycle of chemotherapy. The average reduction in the 2nd reading was ir- respective of whether baseline value was normal or not. The average reduction was statistically significant (P = 0.002; 95% CI, from 0.8369 to 3.49464; t test). 8 out of 10 (80%) patients with partial response had a reduction in their 2nd reading of. CYFRA (P = 0.019; 95% CI, from 0.81965 to 7.20035; t test) which was significant. We also observed that 6/9 (66%) patients whose disease remains stable also had a decrease in their subsequent reading (P = 0.0106; 95% CI, from –0.44942 to 3.82720; t test), though it was not significant statistically. Although 5 out of 9 (55%) patients, who had an increase in their CYFRA 21-1 level, had progressive disease, but it was not statistically significant (P = 0.537; 95% CI, from –1.20021 to 2.13354; t test). 14 out of 19 (73%) who either had partial response or had stable disease, had a reduction in their 2nd value of CYFRA 21-1 and was significant statistically (P = 0.004; 95% CI, from 0.74792 to 3.50208; t test). We also observed that except for 1 patient, all patients who had a decrease of 42% or more in their subsequent CYFRA 21-1 level, were those who had either responded to chemotherapy or had stable disease (P = 0.001), which was statistically significant. Conclusion: We can conclude that monitoring of serum marker CYFRA 21-1, early during first-line chemotherapy may be a useful prognostic tool for evaluation of early tumor response in patients with advanced NSCLC.     

血清肿瘤标志物在肺癌辅助诊断中的应用

目的探讨5种血清肿瘤标志物在肺癌辅助诊断中的应用价值,并选择最理想的血清肿瘤标志物组合。方法应用酶联免疫吸附实验(ELISA)检测170例肺癌患者、50例健康人和60例肺部良性疾病患者血清中神经元特异性烯醇化酶(NSE)、胃泌素释放肽前体(pro GRP)、细胞角蛋白19(CYFRA211)、p53抗体和癌胚抗原(CEA)的水平含量。结果肺癌患者的5种血清肿瘤标志物水平均明显高于健康人组和肺部良性疾病组,差异有统计学意义(P<0.01)。NSE、pro GRP在小细胞肺癌中的水平明显高于其他类型的肺癌(P<0.01),CYFRA211在鳞癌中的水平明显高于其他类型的肺癌(P<0.01)。p53抗体的特异性为100%,NSE、pro GRP对小细胞肺癌检测的敏感性明显高于其他类型的肺癌(P<0.01),CYFRA211对鳞癌检测的敏感性明显高于其他类型的肺癌(P<0.01)。5种血清肿瘤标志物经组合后,敏感性明显高于任一单项肿瘤标志物(P<0.01)。结论5种血清肿瘤标志物对于肺癌的辅助诊断有一定的临床意义。NSE、pro GRP二者可作为联合检测小细胞肺癌的首选标志物,CYFRA211、CEA和p53抗体三者可作为联合检测非小细胞肺癌的首选标志物。p53抗体对肺癌的辅助诊断有很高的特异性,CYFRA211对鳞癌的辅助诊断有一定的作用。     

肺癌患者化疗前后外周血肿瘤标志物水平变化的临床价值

目的 对肺癌患者化疗前后外周血内肿瘤标志物水平改变进行分析.方法 随机选取50例肺癌患者,给予紫杉醇类或联合顺铂方案化疗2个周期,采用放射免疫技术对不同病理类型组化疗前后外周血内肿瘤标志物CEA、NSE、CYFRA 21-1水平进行监测,并结合化疗前后肺部CT影像学变化分析化疗前各病理类型血清肿瘤外周血内肿瘤标志物水平.结果 50例患者经2个周期化疗后,行CT影像学检测评估,肿块PR+ CR者38例,NC+ PD者12例.化疗前,腺癌组血清CEA水平显著高于鳞癌组和小细胞肺癌组;鳞癌组CYFRA 21-1水平显著高于腺癌组和小细胞肺癌;小细胞肺癌组NSE水平显著高于腺癌组和鳞癌组,数据对比差异均具有统计学意义(P＜0.05).腺癌组(CR+ PR)化疗后CEA水平显著低于化疗前;鳞癌组(CR+ PR)化疗后CYFRA 21-1水平显著低于化疗前;小细胞肺癌组(CR+ PR)化疗后NSE水平显著低于化疗前,数据对比差异均具有统计学意义(P＜0.05).结论 通过检测外周血内肿瘤标志物CEA、NSE、CYFRA 21-1水平改变可用于化疗疗效判定,具有简便、经济的特点.     

胸水和血清CEA、CA125、CYFRA21-1、NSE和Pro-GRP联合检测对肺癌的诊断价值

目的:探讨联合检测肺癌胸水和血清中癌胚抗原(CEA)、癌抗原125(CA125)、细胞角蛋白19片段(CYFRA21-1)、神经原特异性烯醇化酶(NSE)和胃泌素释放肽前体(Pro-GRP)5 种肿瘤标志物水平在肺癌临床诊断中的应用价值,以期提高鉴别良恶性胸水的能力。方法:用电化学发光法检测93例肺癌患者和54例肺炎性疾病患者的血清及胸水标本CEA、CA125、CYFRA21-1、NSE和Pro-GRP水平。结果:癌性胸水组中CEA、CA125、CYFRA21-1、NSE和Pro-GRP 5种肿瘤标志物平均水平与炎性胸水组比较,差别均有统计学意义(P<0.05);癌性胸水组中CEA、CYFRA21-1、CA125的含量远远高于炎性胸水组（20~600倍）(P<0.01)。肺癌胸水组中CEA、CA125、CYFRA21-1、NSE和Pro-GRP 5种肿瘤标志物水平与肺癌血清组比较,差别均有统计学意义(P<0.05)。肺癌胸水组中CEA、CYFRA21-1、CA125的含量远远高于肺癌血清组（7~80倍）(P<0.01),相比与正常对照组更是有200倍以上的增高(P<0.01),因此胸水中CEA、CYFRA21-1、CA125百倍左右的升高提示恶性肿瘤的存在。将93例癌性胸水和血清分为腺癌、鳞癌和小细胞癌。腺癌、鳞癌和小细胞癌胸水组中CEA、CA125、CYFRA21-1、NSE和Pro-GRP 5种肿瘤标志物含量明显高于炎性胸水组(P<0.01);腺癌胸水组中CEA含量明显高于鳞癌和小细胞癌(P<0.01);鳞癌胸水组中CYFRA21-1含量明显高于腺癌和小细胞癌(P<0.01);小细胞癌胸水组中NSE和Pro-GRP含量明显高于腺癌和鳞癌(P<0.01)。CA125含量在胸水组中腺癌、鳞癌含量明显高于小细胞癌(P<0.01)。5 种标志物单项及联合检测的灵敏度肺癌胸水组均高于肺癌血清组,肺癌胸水中5项联合检测后灵敏度可达99.11%。结论:肺癌组胸水中CEA、CA125、CYFRA21-1、NSE和Pro-GRP 5种肿瘤标志物联合检测有利于良恶性胸水的鉴别诊断,联合检测可以提高肺癌诊断的灵敏度,当肿瘤标志物显著升高时,CEA可作为肺腺癌的肿瘤标志物;CYFRA21-1可作为肺鳞癌的肿瘤标志物;NSE和Pro-GRP可作为小细胞癌的肿瘤标志物;CA125可作为非小细胞肺癌的肿瘤标志物。     

Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer

BACKGROUND: The authors assessed the predictive and prognostic role of decline in the serum levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA 21-1) during chemotherapy in patients with advanced nonsmall cell lung cancer (NSCLC). METHODS: Changes in serum levels of CEA and CYFRA 21-1 during first-line, conventional chemotherapy were studied prospectively with an immunometric assay at baseline and every 2 courses in 117 patients with advanced NSCLC. Data were correlated with radiologic objective response (OR) and survival. RESULTS: One hundred seven patients were evaluable for radiologic and serologic response assessment after 2 chemotherapy courses. The radiologic OR rate was 44% overall. The CEA and CYFRA 21-1 responses (> or =20% reduction over baseline level; assessed after the second course of chemotherapy) were 38% and 61%, respectively. Statistically significant correlations were observed between CEA and CYFRA 21-1 responses and OR (P = .01 and P = .004, respectively). The median survival from response assessment (landmark analysis) was 9 months. In a univariate analysis, disease stage, performance status, baseline lactate dehydrogenase level (LDH), OR, CEA response, and CYFRA 21-1 response were correlated significantly with survival. In particular, the median survival was 13 months for patients who had a CEA response and 11 months for patients who had a CYFRA 21-1 response compared with 8 months and 6 months for patients who did not respond, respectively. In a multivariate analysis, performance status (P = .005), baseline LDH level (P = .02), CEA response (P = .03) and CYFRA 21-1 response (P = .01) were confirmed as independent prognostic factors for survival. CONCLUSIONS: CEA and CYFRA 21-1 responses appeared to be reliable surrogate markers of chemotherapy efficacy in patients with advanced NSCLC.     

血清CYFRA21-1、SCC-Ag、LDH联合检测对肺鳞癌与肺部感染鉴别诊断的价值初探

目的:探讨血清SCC-Ag、CYFRA21-1、LDH联合检测对肺鳞癌与肺部感染鉴别诊断的价值。方法:回顾性分析2017年1月至2018年3月北京市和平里医院消化科及呼吸科住院或门诊就诊的110例患者,其中肺鳞癌患者55例,肺部感染患者55例,使用化学发光法和速率法分别检测血清CYFRA21-1、SCC-Ag、LDH表达水平,以及肺鳞癌患者Ⅰ-Ⅳ期CYFRA21-1、SCC-Ag表达水平,经统计学处理后对比分析。结果:肺鳞癌组患者血清CYFRA21-1高于肺部感染组患者,差异有统计学意义(P<0.05);同时肺部感染组患者血清SCC-Ag表达高于肺鳞癌组,有统计学差异(P<0.05);Ⅰ期、Ⅱ期肺鳞癌组患者血清CYFRA21-1较Ⅳ期患者相比差异显著,随着肿瘤的进展,血清CYFRA21-1、SCC-Ag均有上升的趋势;肺鳞癌组患者血清LDH表达水平显著高于肺部感染组患者(P<0.01)。结论:独立的每个肿瘤标志物因其自身的特异性和敏感性,可能导致诊断的局限性,血清CYFRA21-1、SCC-Ag、LDH联合检测对肺鳞癌与肺部感染辅助鉴别诊断可能具有一定临床价值。